Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
Browsing: 1144
The New York Times reports that about 75 percent of patients taking telaprevir in combination with existing hepatitis C drugs were essentially cured of the virus, compared to 44 percent on standard therapy alone.